Quantifies cutaneous phosphorylated alpha-synuclein in mild cognitive impairment, suggesting potential biomarkers for Alzheimer's disease and dementia with Lewy bodies.
To quantify cutaneous phosphorylated alpha-synuclein (P-SYN) deposition in patients with mild cognitive impairment (MCI) due to suspected Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).
No takes yet. Share an insight, caveat, or question.
Freeman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: